Literature DB >> 26476535

Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma.

Moqin Qiu1, Yingchun Liu2, Xiangyuan Yu3, Linyuan Qin3, Chunhua Bei3, Xiaoyun Zeng4, Xiaoqiang Qiu4, Bo Tang1, Songqing He1, Hongping Yu5.   

Abstract

The p53 tumor suppressor and its negative regulator, murine double minute 2 (MDM2), play critical roles in carcinogenesis. P53 codon 72 and MDM2 309T>G polymorphisms could influence p53 and MDM2 function, respectively, and might affect cancer susceptibility. We therefore investigated the association between these two SNPs, alone or in combination, and the risk of hepatocellular carcinoma (HCC) in Chinese. In this case-control study, we genotyped p53 codon 72 and MDM2 309T>G polymorphisms in 985 HCC cases and 992 cancer-free age- and sex-matched controls and evaluated their associations with the risk of HCC. Although no significant main effects were found for these two SNPs in the single-locus analysis and stratified analysis by age, sex, smoking, drinking, and hepatitis B virus (HBV) infection, we found that individuals carrying at least one G allele of the MDM2 309T>G polymorphism had statistically significant increased risk of HCC among those with the p53 Pro/Pro genotype (adjusted odds ratio (OR) = 2.23, 95 % confidence interval (95%CI) = 1.20-4.14 for TG genotype; adjusted OR = 2.67, 95%CI = 1.32-5.42 for GG genotype), and the interaction between p53 codon 72 and MDM2 309T>G was significant (P interaction = 0.017). Our findings suggest that the interaction of p53 codon 72 and MDM2 309T>G may play an important role in the etiology of HCC. More studies with well-designed and large sample sizes are required to validate these observations.

Entities:  

Keywords:  Hepatocellular carcinoma; MDM2; Risk; Single-nucleotide polymorphism; p53

Mesh:

Substances:

Year:  2015        PMID: 26476535     DOI: 10.1007/s13277-015-4222-4

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  46 in total

1.  Analysis of genetic damage and gene polymorphism in hepatocellular carcinoma (HCC) patients in a South Indian population.

Authors:  Subramaniam Mohana Devi; Vellingiri Balachandar; Meyyazhagan Arun; Shanmugam Suresh Kumar; Balasubramanian Balamurali Krishnan; Keshavarao Sasikala
Journal:  Dig Dis Sci       Date:  2012-10-02       Impact factor: 3.199

Review 2.  The NQO1 C609T polymorphism and hepatocellular carcinoma risk.

Authors:  Yonggang Fan; Dingwen Hu; Bing Feng; Wei Wang
Journal:  Tumour Biol       Date:  2014-02-16

3.  Serum p53 gene polymorphisms and severity of hepatitis B or C-related chronic liver diseases in Taiwan.

Authors:  Yone-Han Mah; Ching-Sheng Hsu; Chen-Hua Liu; Chun-Jen Liu; Ming-Yang Lai; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2011-02-06       Impact factor: 6.047

4.  Impact of TP53 codon 72 and MDM2 promoter 309 allelic dosage in a Moroccan population with hepatocellular carcinoma.

Authors:  Sayeh Ezzikouri; Abdellah Essaid El Feydi; Rajae Afifi; Mustapha Benazzouz; Mohammed Hassar; Pascal Pineau; Soumaya Benjelloun
Journal:  Int J Biol Markers       Date:  2011 Oct-Dec       Impact factor: 2.659

Review 5.  Environmental factors and risk for hepatocellular carcinoma.

Authors:  Mimi C Yu; Jian-Min Yuan
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

6.  MDM2 SNP309T>G polymorphism increases susceptibility to hepatitis B virus-related hepatocellular carcinoma in a northeast Han Chinese population.

Authors:  Xi Wang; Xuelong Zhang; Bing Qiu; Yinhua Tang; He Sun; Hongfei Ji; Yan Liu; Lijun Shi; Guang Song; Youlin Yang
Journal:  Liver Int       Date:  2012-03-14       Impact factor: 5.828

7.  Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53.

Authors:  W Tao; A J Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

8.  Mutations of the p53 gene in lymphoid leukemia.

Authors:  K Sugimoto; H Toyoshima; R Sakai; K Miyagawa; K Hagiwara; H Hirai; F Ishikawa; F Takaku
Journal:  Blood       Date:  1991-03-15       Impact factor: 22.113

9.  Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma.

Authors:  Myung Su Son; Moon Ju Jang; Young Joo Jeon; Won Hee Kim; Chang-Il Kwon; Kwang Hyun Ko; Pil Won Park; Sung Pyo Hong; Kyu Sung Rim; Sung Won Kwon; Seong Gyu Hwang; Nam Keun Kim
Journal:  Gene       Date:  2013-04-28       Impact factor: 3.688

10.  Altered patterns of MDM2 and TP53 expression in human bladder cancer.

Authors:  P Lianes; I Orlow; Z F Zhang; M R Oliva; A S Sarkis; V E Reuter; C Cordon-Cardo
Journal:  J Natl Cancer Inst       Date:  1994-09-07       Impact factor: 13.506

View more
  5 in total

1.  Relationships between cell cycle pathway gene polymorphisms and risk of hepatocellular carcinoma.

Authors:  Yue-Li Nan; Yan-Ling Hu; Zhi-Ke Liu; Fang-Fang Duan; Yang Xu; Shu Li; Ting Li; Da-Fang Chen; Xiao-Yun Zeng
Journal:  World J Gastroenterol       Date:  2016-06-28       Impact factor: 5.742

2.  Influence of MDM2 polymorphisms on squamous cell carcinoma susceptibility: a meta-analysis.

Authors:  Huanxin Yu; Haiyan Li; Jinling Zhang; Gang Liu
Journal:  Onco Targets Ther       Date:  2016-10-11       Impact factor: 4.147

3.  The Interaction of Smoking with Gene Polymorphisms on Four Digestive Cancers: A Systematic Review and Meta-Analysis.

Authors:  Le Du; Lei Lei; Xiaojuan Zhao; Hongjuan He; Erfei Chen; Jing Dong; Yuan Zeng; Jin Yang
Journal:  J Cancer       Date:  2018-04-06       Impact factor: 4.207

4.  Association between MDM2 SNP309, p53 Arg72Pro, and hepatocellular carcinoma risk: A MOOSE-compliant meta-analysis.

Authors:  Xiaohua Duan; Jingquan Li
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

5.  The frequency of TP53 R72P and MDM2 309T>G polymorphisms in Iranian infertile men with spermatogenetic failure: A case-control study.

Authors:  Zeinab Ebrahim Abadi; Maryam Khademi Bami; Maryam Golzadeh; Seyed Mehdi Kalantar; Mohammad Hasan Sheikhha
Journal:  Int J Reprod Biomed       Date:  2018-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.